<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255044</url>
  </required_header>
  <id_info>
    <org_study_id>48</org_study_id>
    <nct_id>NCT03255044</nct_id>
  </id_info>
  <brief_title>Comparison of Lipophilic Versus Hydrophilic Statins on Patients With Heart Failure</brief_title>
  <official_title>Impact of Lipophilic Versus Hydrophilic Statin Administration on The Clinical Outcome and Cardiac Markers of Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a controversy whether statins are beneficial in patients with heart failure or not.
      Trials in which lipophilic statins have been used revealed positive results, unlike major
      studies where hydrophilic statins were administered. This trial is designed to compare the
      effects of lipophilic versus hydrophilic statin use in patients with heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular End-diastolic volume (LVEDV)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular End-systolic volume (LVESV)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiac markers</measure>
    <time_frame>6 months</time_frame>
    <description>NT pro BNP (N-terminal prohormone of brain natriuretic peptide) sST2 (soluble suppression of tumorigenicity 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living with Heart Failure Questionnaire( MLHFQ)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Packer composite outcome</measure>
    <time_frame>6 months</time_frame>
    <description>Patients are considered improved if at the final visit they experienced a favorable change in NYHA functional class or in the patient global assessment: markedly/moderately improved (or both) but did not experience any major adverse clinical events during the course of the trial (death or hospitalization).
Patients are considered worse if they experienced a major clinical event during the duration of treatment or reported worsening of their NYHA class or global assessment at the final visit.
Patients are considered unchanged if they are neither improved nor worse.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of major adverse cardiac events</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiovascular death
All cause death
Non- fatal myocardial infarction
Stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Hospitalization</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as hospitalization for worsening of heart failure for more than 24 hours and demanding aggressive intervention (IV inotropics, diuretics etc..)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Lipophilic statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 40 mg administered daily in addition to guideline directed therapy for heart failure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrophilic statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 20 mg administered daily in addition to guideline directed therapy for heart failure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin administered as well as standard heart failure therapy</description>
    <arm_group_label>Lipophilic statin</arm_group_label>
    <other_name>standard heart failure therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin administered as well as standard heart failure therapy</description>
    <arm_group_label>Hydrophilic statin</arm_group_label>
    <other_name>standard heart failure therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>guideline directed therapy</intervention_name>
    <description>standard heart failure therapy</description>
    <arm_group_label>Lipophilic statin</arm_group_label>
    <arm_group_label>Hydrophilic statin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  older than 18 years (of both sexes)

          -  diagnosed with stable chronic heart failure NYHA class II-III

          -  ejection fraction &lt; 40 % as assessed by 2D echocardiography

          -  who have been optimized on Guideline Directed treatment for heart failure for at least
             a month prior to enrolling.

        Exclusion Criteria:

          -  Known hypersensitivity to statin

          -  Treatment with statins during the past month prior to study.

          -  Serum creatinine &gt; 3 mg/dl

          -  Significant liver disease: liver enzymes 2.5 folds the upper normal limit

          -  Malignancy

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University Hospital Cardiology Rehab Unit</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hazem Khorshid, PhD</last_name>
      <phone>+201227442219</phone>
      <email>hazemkhorshid@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Nouran Omar, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>August 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Nouran Omar</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <keyword>statin</keyword>
  <keyword>hydrophilic</keyword>
  <keyword>lipophilic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

